Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008
暂无分享,去创建一个
R. Pieters | R. Pieters | H. Dombret | A. Baruchel | E. Macintyre | M. Schrappe | H. Cavé | J. Dongen | G. Henze | J. Starý | K. Schmiegelow | A. Fielding | M. Kneba | V. Asnafi | J. Ribera | A. Goldstone | A. Schrauder | O. Ottmann | A. Biondi | R. Foa | A. Biondi | M. Dworzak | Y. Benoît | N. Goulden | D. Hoelzer | A. Goldstone | A. Rambaldi | M Dworzak | A Biondi | M Schrappe | M. Brüggemann | T. Raff | H. Pfeifer | R. Bassan | A. Fielding | N. Gökbuget | N. Goulden | G. Janka‐Schaub | O. Spinelli | A. Stackelberg | H Dombret | A Baruchel | J Stary | R Pieters | A Rambaldi | J J M van Dongen | G E Janka-Schaub | G Henze | R Foà | H Pfeifer | K Schmiegelow | H Cavé | D Hoelzer | V Asnafi | M Brüggemann | A H Goldstone | A Schrauder | T Raff | O G Ottmann | R Bassan | Y Benoit | A K Fielding | N Gökbuget | N Goulden | E A Macintyre | J-M Ribera | O Spinelli | A von Stackelberg | M Kneba | Josep-Maria Ribera | Alessandro Rambaldi | Josep-María Ribera | A. Rambaldi
[1] Yoo-Jin Kim,et al. Risk factors for adults with Philadelphia‐chromosome‐positive acute lymphoblastic leukaemia in remission treated with allogeneic bone marrow transplantation: the potential of real‐time quantitative reverse‐transcription polymerase chain reaction , 2003, British journal of haematology.
[2] Elaine Coustan-Smith,et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia , 1998, The Lancet.
[3] D. Campana,et al. Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia. , 2002, Blood.
[4] M. Kneba,et al. Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials. , 2007, Blood.
[5] W. Hop,et al. Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL. , 2002, Blood.
[6] G. Lenz,et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph^+ALL) , 2006 .
[7] F. Watzinger,et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) – a Europe against cancer program , 2003, Leukemia.
[8] E. Mejstrikova,et al. Quantification of fusion transcript reveals a subgroup with distinct biological properties and predicts relapse in BCR/ABL-positive ALL: implications for residual disease monitoring , 2009, Leukemia.
[9] T. Barbui,et al. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia. , 2007, Haematologica.
[10] Giuseppe Basso,et al. Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: Multicentric assessment is feasible , 2008, Cytometry. Part B, Clinical cytometry.
[11] K. Schmiegelow,et al. Post-induction residual disease in translocation t(12;21)-positive childhood ALL. , 2003, Medical and pediatric oncology.
[12] M. Relling,et al. Childhood Acute Lymphoblastic Leukaemia , 2007 .
[13] F. Mandelli,et al. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. GIMEMA-AIEOP Multicenter "AIDA" Trial. , 1998, Blood.
[14] J. Hancock,et al. Minimal residual disease analysis for the prediction of relapse in children with standard‐risk acute lymphoblastic leukaemia , 1998, British journal of haematology.
[15] Norma Gutiérrez,et al. Minimal residual disease in adolescent ( older than 14 years ) and adult acute lymphoblastic leukemias : early immunophenotypic evaluation has high clinical value , 2003 .
[16] M. Mancini,et al. A prospective study of residual-disease monitoring of the ALL1/AF4 transcript in patients with t(4;11) acute lymphoblastic leukemia. , 2000, Blood.
[17] Jeremy Hancock,et al. Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center setting; , 2009, Haematologica.
[18] J. Hancock,et al. Minimal Residual Disease Status Before Allogeneic Bone Marrow Transplantation Is an Important Determinant of Successful Outcome for Children and Adolescents With Acute Lymphoblastic Leukemia , 1998 .
[19] J. Dongen,et al. Non-specific amplification of patient-specific Ig/TCR gene rearrangements depends on the time point during therapy: implications for minimal residual disease monitoring , 2008, Leukemia.
[20] E. Thiel,et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. , 2006, Blood.
[21] J. V. Dongen,et al. Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL , 2002, Leukemia.
[22] E. Thiel,et al. Prospective BCR-ABL analysis by polymerase chain reaction (RT-PCR) in adult acute B-lineage lymphoblastic leukemia: reliability of RT-nested-PCR and comparison to cytogenetic data , 2001, Leukemia.
[23] A. Porwit,et al. Quality Control of Flow Cytometry Data Analysis for Evaluation of Minimal Residual Disease in Bone Marrow From Acute Leukemia Patients During Treatment , 2009, Journal of pediatric hematology/oncology.
[24] H. Cavé,et al. A competitive PCR-based method using TCRD, TCRG and IGH rearrangements for rapid detection of patients with high levels of minimal residual disease in acute lymphoblastic leukemia , 2002, Leukemia.
[25] M. Schrappe,et al. MRD at the end of induction therapy in childhood acute lymphoblastic leukemia: outcome prediction strongly depends on the therapeutic regimen , 2001, Leukemia.
[26] Marina Ruggeri,et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders , 2008, Haematologica.
[27] J. Dongen,et al. Rearranged T-cell receptor beta genes represent powerful targets for quantification of minimal residual disease in childhood and adult T-cell acute lymphoblastic leukemia , 2004, Leukemia.
[28] J. V. Dongen,et al. T cell receptor gamma gene rearrangements as targets for detection of minimal residual disease in acute lymphoblastic leukemia by real-time quantitative PCR analysis , 2002, Leukemia.
[29] J. Gabert,et al. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects , 2003, Leukemia.
[30] A. Borkhardt,et al. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] H. Cavé,et al. Clinical Significance of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia , 1998 .
[32] J. V. van Dongen,et al. Immunophenotypic changes between diagnosis and relapse in childhood acute lymphoblastic leukemia. , 1995, Leukemia.
[33] H. Cavé,et al. Prospective monitoring and quantitation of residual blasts in childhood acute lymphoblastic leukemia by polymerase chain reaction study of delta and gamma T-cell receptor genes. , 1994, Blood.
[34] D. Campana,et al. Methodological approach to minimal residual disease detection by flow cytometry in adult B-lineage acute lymphoblastic leukemia. , 2006, Haematologica.
[35] J. V. van Dongen,et al. Molecular monitoring of residual disease using antigen receptor genes in childhood acute lymphoblastic leukaemia. , 2002, Best practice & research. Clinical haematology.
[36] A. Órfão,et al. Immunophenotypic analysis of mast cells in mastocytosis: When and how to do it. Proposals of the Spanish Network on Mastocytosis (REMA) , 2004, Cytometry. Part B, Clinical cytometry.
[37] J. Dongen,et al. TCRB gene rearrangements in childhood and adult precursor-B-ALL: frequency, applicability as MRD-PCR target, and stability between diagnosis and relapse , 2004, Leukemia.
[38] F. Mandelli,et al. Therapy of molecular relapse in acute promyelocytic leukemia. , 1999, Blood.
[39] G. Basso,et al. CD99 expression in T-lineage ALL: implications for flow cytometric detection of minimal residual disease , 2004, Leukemia.
[40] J. V. van Dongen,et al. Analysis of Ig and T-cell receptor genes in 40 childhood acute lymphoblastic leukemias at diagnosis and subsequent relapse: implications for the detection of minimal residual disease by polymerase chain reaction analysis. , 1994, Blood.
[41] M. D. Den Boer,et al. Effect of the histone deacetylase inhibitor depsipeptide on B-cell differentiation in both TEL-AML1-positive and negative childhood acute lymphoblastic leukemia. , 2005, Haematologica.
[42] J. V. van Dongen,et al. tal-1 deletions in T-cell acute lymphoblastic leukemia as PCR target for detection of minimal residual disease. , 1993, Leukemia.
[43] W. Hop,et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood , 1998, The Lancet.
[44] J. Dongen,et al. MRD detection in acute lymphoblastic leukemia patients using Ig/TCR gene rearrangements as targets for real-time quantitative PCR. , 2009 .
[45] Francisco Cervantes,et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. , 2006, Blood.
[46] A Orfao,et al. 2006 Bethesda International Consensus recommendations on the flow cytometric immunophenotypic analysis of hematolymphoid neoplasia: Medical indications , 2007, Cytometry. Part B, Clinical cytometry.
[47] Yoo-Jin Kim,et al. Minimal residual disease-based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia. , 2003, Blood.
[48] Dario Campana,et al. Minimal residual disease in acute lymphoblastic leukemia. , 2010, Hematology. American Society of Hematology. Education Program.
[49] J. Hancock,et al. Minimal residula disease status as a predictor of relapse after allogenic bone marrow transplantation for children with acute lymphoblastic leukaemia , 1998, British journal of haematology.
[50] R. Pieters,et al. Post-induction residual leukemia in childhood acute lymphoblastic leukemia quantified by PCR correlates with in vitro prednisolone resistance , 2001, Leukemia.
[51] C. V. D. Schoot,et al. Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR , 2002, Leukemia.
[52] H. Dombret,et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] Michael N Dworzak,et al. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. , 2002, Blood.
[54] J. Radich,et al. Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation. , 1997, Blood.
[55] J. Dongen,et al. Comparative analysis of T-cell receptor gene rearrangements at diagnosis and relapse of T-cell acute lymphoblastic leukemia (T-ALL) shows high stability of clonal markers for monitoring of minimal residual disease and reveals the occurrence of second T-ALL , 2003, Leukemia.
[56] H. Dombret,et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] F. Behm,et al. Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. , 2002, Blood.
[58] C. Preudhomme,et al. Good correlation between RT-PCR analysis and relapse in Philadelphia (Ph1)-positive acute lymphoblastic leukemia (ALL) , 1997, Leukemia.
[59] J. V. van Dongen,et al. MRD detection in acute lymphoblastic leukemia patients using Ig/TCR gene rearrangements as targets for real-time quantitative PCR. , 2009, Methods in molecular biology.
[60] K. Schmiegelow,et al. Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome. , 2002, Blood.
[61] C. E. Pedreira,et al. Harmonization of light scatter and fluorescence flow cytometry profiles obtained after staining peripheral blood leucocytes for cell surface‐only versus intracellular antigens with the Fix & Perm™ reagent , 2009, Cytometry. Part B, Clinical cytometry.
[62] J. Cayuela,et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data , 2007, Leukemia.
[63] E S Costa,et al. A probabilistic approach for the evaluation of minimal residual disease by multiparameter flow cytometry in leukemic B‐cell chronic lymphoproliferative disorders , 2008, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[64] U. Jaeger,et al. Quantification of minimal residual disease in patients with BCR‐ABL‐positive acute lymphoblastic leukaemia using quantitative competitive polymerase chain reaction , 1999, British journal of haematology.
[65] Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood , 1998 .
[66] S. Hunger,et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. , 2008, Blood.
[67] E. Mejstrikova,et al. B-cell reconstitution after allogeneic SCT impairs minimal residual disease monitoring in children with ALL , 2008, Bone Marrow Transplantation.
[68] D. Campana. Determination of minimal residual disease in leukaemia patients , 2003, British journal of haematology.
[69] R. Foà,et al. Outcome prediction by immunophenotypic minimal residual disease detection in adult T‐cell acute lymphoblastic leukaemia , 2003, British journal of haematology.
[70] R. Foà,et al. Gruppo Italiano Malattie Ematologiche dell ' Adulto ( GIMEMA ) acute lymphoblastic leukemia without additional chemotherapy : results survival in elderly Philadelphia chromosome – positive patients with Imatinib plus steroids induces complete remissions and prolonged , 2007 .
[71] M. Björkholm,et al. Analysis of minimal residual disease in childhood acute lymphoblastic leukemia: comparison between RQ-PCR analysis of Ig/TcR gene rearrangements and multicolor flow cytometric immunophenotyping , 2004, Leukemia.
[72] F. Behm,et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. , 2000, Blood.
[73] D. Campana,et al. Minimal Residual Disease Studies by Flow Cytometry in Acute Leukemia , 2004, Acta Haematologica.
[74] J. Esteve,et al. Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial , 2010, Haematologica.
[75] V. Preedy,et al. European Organization for Research and Treatment of Cancer , 2010 .
[76] D. Grimwade,et al. Acute promyelocytic leukemia: a model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia , 2002, Leukemia.
[77] G. Basso,et al. Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection , 2005, Leukemia.
[78] Maria Grazia Valsecchi,et al. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[79] G. Basso,et al. Expression of CD 58 in normal , regenerating and leukemic bone marrow B cells : implications for the detection of minimal residual disease in acute lymphocytic leukemia , 2003 .
[80] E. Mejstrikova,et al. Minimal residual disease (MRD) analysis in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: is it possible to avoid MRD testing? , 2008, Leukemia.
[81] D. Campana,et al. Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia , 2004, Leukemia.
[82] H. Gschaidmeier,et al. Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571). , 2003, Blood.
[83] J. Mazur,et al. Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia , 2003, Leukemia.
[84] T. Barbui,et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). , 2009, Blood.
[85] G. Basso,et al. CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy. , 2008, Blood.
[86] G. Specchia,et al. Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia , 2005, Leukemia.
[87] C. E. Pedreira,et al. Generation of flow cytometry data files with a potentially infinite number of dimensions , 2008, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[88] M. van der Burg,et al. Comparative analysis of Ig and TCR gene rearrangements at diagnosis and at relapse of childhood precursor-B-ALL provides improved strategies for selection of stable PCR targets for monitoring of minimal residual disease. , 2002, Blood.
[89] L. Foroni,et al. Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[90] C. Eckert,et al. Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia , 2001, The Lancet.
[91] A. Órfão,et al. Flow cytometric analysis of cerebrospinal fluid samples and its usefulness in routine clinical practice. , 2002, American journal of clinical pathology.